Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback